At a glance
- Originator AstraZeneca
- Class Antineoplastics
- Mechanism of Action Thymidylate synthase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Leukaemia
Most Recent Events
- 09 Aug 2000 Discontinued-Preclinical for Leukaemia in United Kingdom (Unknown route)
- 07 Apr 1999 Merger of Astra and Zeneca to form AstraZeneca completed.
- 21 Mar 1997 Preclinical development for Leukaemia in United Kingdom (Unknown route)